TVRD — Tvardi Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program And Extends Cash Runway Into 2026
Cara Therapeutics hits all-time low after ending skin disease therapy trial
Brief: Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study
U.S. RESEARCH ROUNDUP-Aclaris Therapeutics, Beauty Health Co, Vicarious Surgical
Brief: Cara Therapeutics Q3 Revenue USD 4.9 Million Vs. IBES Estimate USD 9.95 Million
U.S. RESEARCH ROUNDUP-Aerovironment, Hubspot, Oracle
U.S. RESEARCH ROUNDUP-Celanese, Draftkings, Sovos Brands
U.S. RESEARCH ROUNDUP-Alteryx, Axsome Therapeutics, Inogen
Cara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cara Therapeutics Q2 Revenue USD 6.9 Million Vs. IBES Estimate USD 6.56 Million
Cara Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Equitrans Midstream, Hasbro, Humana
Brief: Kapruvia® (Difelikefalin) Recommended By England's NICE For Treatment Of Adults With Moderate-To-Severe CKD-Associated Pruritus
Cara Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cara Therapeutics Reports First Quarter 2023 Financial Results
Brief: Cara Therapeutics posts Q1 revenue USD 6.2 million
Cara Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Cara Therapeutics Inc - Informs Its Investors That It Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
U.S. STOCKS ON THE MOVE-BlackSky, Squarespace, Virax Biolabs